Dual Antiplatelet Therapy
ESC guideline may help risk stratify patients with non ST-elevation ACS undergoing PCI
The 2020 European Society of Cardiology guidelines for the management of non ST-elevation ACS may help clinicians determine the thrombotic risk categories of patients being considered for PCI, a speaker reported.
Ticagrelor monotherapy after PCI poses no extra revascularization risk vs. continued DAPT
Ticagrelor monotherapy after 3-month dual antiplatelet therapy was not associated with greater risk for repeat revascularization or MACCE at 1 year after PCI vs. continued DAPT, a speaker reported.
HOST-IDEA
Comparing single antiplatelet therapy after 3-month DAPT with 12-month DAPT after PCI with third-generation DES with the thinnest struts.
3-month DAPT noninferior to 12-month after PCI using third-generation stents
NEW ORLEANS — An all-comers trial excluding patients with STEMI showed that after PCI, 3-month dual antiplatelet therapy was noninferior to 12-month DAPT for the composite outcome of net adverse clinical events, a speaker reported.
Asundexian may not prevent second stroke after small subcortical infarct
A secondary analysis of the phase 2 PACIFIC-STROKE trial showed that asundexian is effective for the secondary prevention of stroke in patients with stroke of atherosclerotic origin, but not those with small subcortical infarcts.
OPTION: Feasible to replace aspirin with indobufen in DAPT after PCI
CHICAGO — In patients who had PCI with a drug-eluting stent, dual antiplatelet therapy with indobufen plus clopidogrel was noninferior to DAPT with aspirin plus clopidogrel, according to the results of the OPTION trial.
Shift to ‘personalized’ DAPT after PCI must balance complex bleeding, ischemic risks
For adults who undergo PCI with a drug-eluting stent, recommendations for dual antiplatelet therapy have evolved from a standard 1-year duration for most patients to a more nuanced approach that balances risks for ischemia and bleeding.
Long-term P2Y12 inhibitor monotherapy after PCI reduces bleeding at 3 years vs. DAPT
Long-term P2Y12 inhibition after PCI reduced bleeding at 3 years compared with dual antiplatelet therapy, with no significant differences observed for ischemic events, according to new data from the SMART-CHOICE trial.
FDA expands LAA closure device labeling to include 45-day DAPT option
Boston Scientific announced the FDA indication for its left atrial appendage closure device has been expanded to include a 45-day dual antiplatelet therapy option after treatment of patients with nonvalvular atrial fibrillation.
No long-term ischemic risk with 1-month DAPT after PCI in high-risk patients
In adults with high bleeding risk, early deintensification of dual antiplatelet therapy after PCI was associated with less bleeding and no increased ischemic risk beyond 12 months vs. standard treatment, according to a speaker.